AWM Investment Company Inc. Has $36.92 Million Position in Definium Therapeutics, Inc. $DFTX

Key Points

• AWM Investment Company reduced its Definium Therapeutics stake by 27.1% in the second quarter, selling 292,093 shares. It still held 784,800 shares worth approximately $36.9 million, representing 3.2% of its portfolio.
• Definium shares opened at $44.81 after rising 3.6%, with a $6.02 billion market capitalization. The company reported a quarterly loss of $1.44 per share, significantly missing the $0.55-per-share consensus estimate.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a $63 consensus price target, although insiders sold 48,096 shares worth about $2.2 million over the past 90 days.

AWM Investment Company Inc. lessened its holdings in Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 27.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 784,800 shares of the company's stock after selling 292,093 shares during the period. Definium Therapeutics accounts for approximately 3.2% of AWM Investment Company Inc.'s portfolio, making the stock its 8th largest holding. AWM Investment Company Inc. owned approximately 0.58% of Definium Therapeutics worth $36,917,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DFTX. Royal Bank of Canada increased its position in shares of Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company's stock worth $382,000 after purchasing an additional 6,148 shares during the last quarter. Creative Planning raised its position in shares of Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company's stock valued at $429,000 after buying an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Definium Therapeutics by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company's stock valued at $315,000 after buying an additional 2,342 shares in the last quarter. Rhumbline Advisers raised its position in shares of Definium Therapeutics by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company's stock valued at $748,000 after buying an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. Institutional investors own 27.91% of the company's stock.

Definium Therapeutics Trading Up 3.6%

NASDAQ DFTX opened at $44.81 on Wednesday. The stock has a market cap of $6.02 billion, a P/E ratio of -13.06 and a beta of 2.23. Definium Therapeutics, Inc. has a fifty-two week low of $8.70 and a fifty-two week high of $49.70. The stock has a 50 day simple moving average of $42.82 and a two-hundred day simple moving average of $28.26. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, analysts forecast that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on DFTX shares. Canaccord Genuity Group set a $64.00 price objective on Definium Therapeutics and gave the company a "buy" rating in a report on Thursday, August 13th. Royal Bank Of Canada upped their target price on Definium Therapeutics from $57.00 to $66.00 and gave the stock an "outperform" rating in a research note on Thursday, August 13th. Oppenheimer reissued an "outperform" rating and set a $70.00 price target on shares of Definium Therapeutics in a research note on Wednesday, August 12th. Wall Street Zen downgraded shares of Definium Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Finally, Bank of America assumed coverage on shares of Definium Therapeutics in a report on Tuesday, August 18th. They issued a "buy" rating and a $75.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $63.00.

Insider Transactions at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the sale, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company's stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 48,096 shares of company stock valued at $2,165,763. Insiders own 2.40% of the company's stock.

Definium Therapeutics Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source